Visualization of Carotid Atherosclerosis by 68Ga-MSA
Primary Purpose
Atherosclerosis, Carotid Atherosclerosis, Noninvasive Imaging of Atherosclerosis
Status
Completed
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
68Gallium-MSA
Sponsored by
About this trial
This is an interventional diagnostic trial for Atherosclerosis focused on measuring positron emission tomography, macrophage, neomannosyl human serum albumin
Eligibility Criteria
Inclusion Criteria:
•coronary artery disease patients with carotid plaques
- control without carotid plaque
Exclusion Criteria:
- •pregnancy, allergy to albumin, any acute or chronic inflammatory disease, hematologic disease, liver disease, renal disease
Sites / Locations
- Department of Nuclear Medicine, Institute of Radiation Medicine,
- Korea University Guro Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Sham Comparator
Arm Label
Atherosclerosis
control
Arm Description
coronary artery disease patients with carotid plaques confirmed by a ultrasound study
no coronary artery disease patients without carotid plaques confirmed by a ultrasound study
Outcomes
Primary Outcome Measures
side reactions at MSA injection site of the skin
development of unexpected skin rashes or other skin lesions at MSA injection site of the skin with 2 hours after MSA injection
unstable changes of vital signs and development of abnormal biochemical parameters
This includes unstable changes of vital signs including blood pressure, body temperature and heart rate, and abnormal changes of biochemical parameters such as hematologic, hepatic and renal functions.
Secondary Outcome Measures
standard uptake unit(SUV) at carotid arteries
SUV at aorta and iliac arteries
Full Information
NCT ID
NCT01893489
First Posted
June 27, 2013
Last Updated
August 23, 2013
Sponsor
Korea University
Collaborators
SHIN JIN MEDICS
1. Study Identification
Unique Protocol Identification Number
NCT01893489
Brief Title
Visualization of Carotid Atherosclerosis by 68Ga-MSA
Official Title
Phase I Study to Evaluated the Safety of Noninvasive Molecular Imaging for the Detection of Inflammation in Carotid Atherosclerotic Lesions by Using Ga-68-NOTA-MSA in Healthy Volunteers and Patients With Coronary Artery Disease
Study Type
Interventional
2. Study Status
Record Verification Date
August 2013
Overall Recruitment Status
Completed
Study Start Date
September 2012 (undefined)
Primary Completion Date
August 2013 (Actual)
Study Completion Date
August 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Korea University
Collaborators
SHIN JIN MEDICS
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Until now, no specific atherosclerosis-targeting agent labeled with positron emitter is not yet available. Investigators developed neomannosyl human serum albumin(MSA) for the terminal mannose residues of MSA binding with the mannose receptors of macrophages in atherosclerosis, and investigators investigate whether 68Ga-MSA can be a novel agent for non-invasive molecular imaging of carotid atherosclerotic lesion in PET.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atherosclerosis, Carotid Atherosclerosis, Noninvasive Imaging of Atherosclerosis
Keywords
positron emission tomography, macrophage, neomannosyl human serum albumin
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Non-Randomized
Enrollment
12 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Atherosclerosis
Arm Type
Active Comparator
Arm Description
coronary artery disease patients with carotid plaques confirmed by a ultrasound study
Arm Title
control
Arm Type
Sham Comparator
Arm Description
no coronary artery disease patients without carotid plaques confirmed by a ultrasound study
Intervention Type
Other
Intervention Name(s)
68Gallium-MSA
Intervention Description
68Gallium-MSA 2.0 mci for Positron Emission Tomogram(PET) imaging
Primary Outcome Measure Information:
Title
side reactions at MSA injection site of the skin
Description
development of unexpected skin rashes or other skin lesions at MSA injection site of the skin with 2 hours after MSA injection
Time Frame
with 2 hours after MSA injection
Title
unstable changes of vital signs and development of abnormal biochemical parameters
Description
This includes unstable changes of vital signs including blood pressure, body temperature and heart rate, and abnormal changes of biochemical parameters such as hematologic, hepatic and renal functions.
Time Frame
24 hours after MSA injection
Secondary Outcome Measure Information:
Title
standard uptake unit(SUV) at carotid arteries
Time Frame
baseline
Title
SUV at aorta and iliac arteries
Time Frame
baseline
10. Eligibility
Sex
All
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
•coronary artery disease patients with carotid plaques
control without carotid plaque
Exclusion Criteria:
•pregnancy, allergy to albumin, any acute or chronic inflammatory disease, hematologic disease, liver disease, renal disease
Facility Information:
Facility Name
Department of Nuclear Medicine, Institute of Radiation Medicine,
City
Seoul
ZIP/Postal Code
110-744
Country
Korea, Republic of
Facility Name
Korea University Guro Hospital
City
Seoul
ZIP/Postal Code
152-703
Country
Korea, Republic of
12. IPD Sharing Statement
Learn more about this trial
Visualization of Carotid Atherosclerosis by 68Ga-MSA
We'll reach out to this number within 24 hrs